Extracted Tables: [{'document_name': 'tobeingest', 'table_id': '7ae24fe2-0677-435d-a373-d96562e235af', 'table_name': 'page_4_table_1.jpg', 'table_bbox': x: 0.506906270980835, y: 0.08016842603683472, width: 0.4142002463340759, height: 0.07551024109125137, 'table_column_count': 2, 'table_title': 'Table 1. Continued', 'column_headers': ['Characteristics\n', 'Patients\n (N = 1000)\n'], 'footers': ["Abbreviations: 5-ASAs, aminosalicylates; BEP; Baccalauréate Professionnel; CAD, Canadian dollars; CAP, Certificate d'Aptitude Professionelle; CEGEP, Collège d'enseignement général et professionnel; n, weighted number of patients with each characteristic; N, number of patients included in the analysis; SD, standard deviation; TNF, tumor necrosis factor; UC, ulcerative colitis; USD, United States dollars.", '"Diagnosed condition; Question: "Have you personally been told by a doctor that you have any of the following health conditions? Please select all that apply" (Patient Survey Questions, Supplementary Data Content 6).', 'batients with a "milder" form of the disease were defined as those who had ever taken a prescription medication for their UC (excluding those who had only taken 5-ASAs, who were defined as having "mild" UC, and who were excluded from this analysis), had taken corticosteroids for <4 of the past 12 months, and had never taken biologic or immunosuppressant therapy. Patients with "moderate to severe" disease were defined as those who had taken corticosteroid treatment for >4 of the past 12 months, or had ever taken a biologic or immunosuppressant for their UC.', 'dN = 756; Japan was excluded from the analysis because this information was not requested in the original UC Narrative survey in Japan.', 'N = 881; France was excluded from the analysis since income was not requested in the original UC Narrative survey in France.', 'United States and Canada: <$50 000 USD, CAD, respectively; Japan: <¥4 000; Finland: <€30 000.', 'United States and Canada: $50 000-99 USD, CAD, respectively; Japan: ¥4 000 000-6 999 999; Finland: €30 000-49 999.', 'United States and Canada: >$100 000 USD, CAD, respectively; Japan: >¥7 000 000; Finland: >€50 000.', 'Includes patients who were not employed but looking for work, not employed and not looking for work, retired, stay-at-home spouses or parents, students, or not working due to disability or illness. United States and Japan: high school degree or less; France: high school diploma or less; Canada: graduated from secondary school or less; Finland: matriculation examinations or less.'], 'table_height': 0.07551024109125137, 'table_metadata': {}, 'table_page_number': 4, 'table_page_id': 'd9dde500-f1b5-41d4-9267-224645ed4fbd', 'table_confidence': 99.0234375, 'table_row_count': 3, 'table_img_path': 'tobeingest\\tables/img\\page_4_table_1.jpg', 'table_html': '<table><tr><th>Characteristics</th><th>Patients\n (N = 1000)</th></tr>\r\n<tr><td>Diagnosis of depression, n (%)</td><td>147 (15)</td></tr>\r\n<tr><td>Diagnosis of anxiety,a n (%)</td><td>210 (21)</td></tr>\r\n</table>', 'table_markdown': '| Characteristics\n                                | Patients\n (N = 1000)\n          |\n|--------------------------------|----------|\n| Diagnosis of depression, n (%) | 147 (15) |\n| Diagnosis of anxiety,a n (%)   | 210 (21) |', 'table_width': 0.4142002463340759, 'table_x': 0.506906270980835, 'table_y': 0.08016842603683472}, {'document_name': 'tobeingest', 'table_id': 'adca6879-2300-46f1-b9b5-59142ef96a64', 'table_name': 'page_4_table_2.jpg', 'table_bbox': x: 0.06540729105472565, y: 0.10099206119775772, width: 0.41950055956840515, height: 0.814930260181427, 'table_column_count': 2, 'table_title': 'Table 1. Patient demographics, baseline disease characteristics, and psychological comorbidities.', 'column_headers': ['Characteristics\n', 'Patients\n (N = 1000)\n'], 'footers': ["United States: job-specific training, some college but no degree, associate degree; Canada: trade-certificate/diploma, certificate or diploma from community college/institution/CEGEP, teaching certificate from provincial department of education, completed some university study but no degree, university certificate or diploma below bachelor level; Japan: junior college degree; France: CAP/BEP (vocational training certificate/technical education certificate), 2-year college degree/associate's degree; Finland: vocational and professional qualifications or polytechnic degree.", "'United States: college degree or more; Canada: bachelor or first professional degree or more; Japan: bachelors or university degree; France: 3-year college degree/bachelor's degree or more; Finland: university degree.", 'educational levels (proportions in employment were 85%, 58%, and 60% for patients with a high, middle, and low edu- cational level, respectively). Males (82%) were more likely to be employed than females (68%; Table, Supplementary Data Content 3).'], 'table_height': 0.814930260181427, 'table_metadata': {}, 'table_page_number': 4, 'table_page_id': 'd9dde500-f1b5-41d4-9267-224645ed4fbd', 'table_confidence': 99.853515625, 'table_row_count': 50, 'table_img_path': 'tobeingest\\tables/img\\page_4_table_2.jpg', 'table_html': '<table><tr><th>Characteristics</th><th>Patients\n (N = 1000)</th></tr>\r\n<tr><td>Age (years), mean (SD)</td><td>41.3 (12.6)</td></tr>\r\n<tr><td><50, n (%)</td><td>753 (75)</td></tr>\r\n<tr><td>>50, n (%)</td><td>247 (25)</td></tr>\r\n<tr><td>Female, n (%)</td><td>498 (50)</td></tr>\r\n<tr><td>Age at UC diagnosis (years), mean (SD)</td><td>32.3 (12.4)</td></tr>\r\n<tr><td>Time since UC diagnosis (years), mean (SD)</td><td>9.0 (9.5)</td></tr>\r\n<tr><td>Time since UC diagnosis, n (%)</td><td></td></tr>\r\n<tr><td><1 year</td><td>49 (5)</td></tr>\r\n<tr><td>1-4 years</td><td>415 (41)</td></tr>\r\n<tr><td>5-9 years</td><td>198 (20)</td></tr>\r\n<tr><td>>10 years</td><td>338 (34)</td></tr>\r\n<tr><td>Time since UC diagnosis, n (%)\n\nSeverity of UC,b n (%)</td><td></td></tr>\r\n<tr><td>Milder UC</td><td>183 (18)</td></tr>\r\n<tr><td>Moderate to severe UC</td><td>817 (82)</td></tr>\r\n<tr><td>Currently in remission</td><td>676 (68)</td></tr>\r\n<tr><td>Time since UC diagnosis, n (%)\n\nSeverity of UC,b n (%)\n\nOverall health, n (%)</td><td></td></tr>\r\n<tr><td>Good/excellent</td><td>447 (45)</td></tr>\r\n<tr><td>Poor/fair</td><td>553 (55)</td></tr>\r\n<tr><td>Time since UC diagnosis, n (%)\n\nSeverity of UC,b n (%)\n\nOverall health, n (%)\n\nPrescription medications ever taken for UC, n (%)</td><td></td></tr>\r\n<tr><td>5-ASAs (mesalamine, mesalazine)</td><td>664 (66)</td></tr>\r\n<tr><td>Corticosteroids</td><td>694 (69)</td></tr>\r\n<tr><td>Biologic therapy</td><td>570 (57)</td></tr>\r\n<tr><td>Anti-TNF biologic</td><td>538 (54)</td></tr>\r\n<tr><td>Other biologic</td><td>120 (16)</td></tr>\r\n<tr><td>Immunosuppressant</td><td>452 (45)</td></tr>\r\n<tr><td>Another prescription medication</td><td>204 (20)</td></tr>\r\n<tr><td>Time since UC diagnosis, n (%)\n\nSeverity of UC,b n (%)\n\nOverall health, n (%)\n\nPrescription medications ever taken for UC, n (%)\n\nPrescription medications currently taking for UC, n (%)</td><td></td></tr>\r\n<tr><td>5-ASAs</td><td>434 (43)</td></tr>\r\n<tr><td>Corticosteroids</td><td>225 (23)</td></tr>\r\n<tr><td>Biologic therapy</td><td>458 (46)</td></tr>\r\n<tr><td>Anti-TNF biologic</td><td>395 (39)</td></tr>\r\n<tr><td>Other biologic</td><td>84 (11)</td></tr>\r\n<tr><td>Immunosuppressant</td><td>287 (29)</td></tr>\r\n<tr><td>Another prescription medication</td><td>110 (11)</td></tr>\r\n<tr><td>Not currently taking prescription medication</td><td>50 (5)</td></tr>\r\n<tr><td>Impact at work, n (%)</td><td>836 (84)</td></tr>\r\n<tr><td>Took time away from work due to their UC, n (%)</td><td>624 (62)</td></tr>\r\n<tr><td>Time since UC diagnosis, n (%)\n\nSeverity of UC,b n (%)\n\nOverall health, n (%)\n\nPrescription medications ever taken for UC, n (%)\n\nPrescription medications currently taking for UC, n (%)\n\nIncome level,e n (%)</td><td></td></tr>\r\n<tr><td>Lowf</td><td>238 (27)</td></tr>\r\n<tr><td>Middle</td><td>317 (36)</td></tr>\r\n<tr><td>High</td><td>284 (32)</td></tr>\r\n<tr><td>Time since UC diagnosis, n (%)\n\nSeverity of UC,b n (%)\n\nOverall health, n (%)\n\nPrescription medications ever taken for UC, n (%)\n\nPrescription medications currently taking for UC, n (%)\n\nIncome level,e n (%)\n\nEmployment status, n (%)</td><td></td></tr>\r\n<tr><td>Not employed</td><td>250 (25)</td></tr>\r\n<tr><td>Part-time employment</td><td>90 (9)</td></tr>\r\n<tr><td>Full-time employment</td><td>661 (66)</td></tr>\r\n<tr><td>Time since UC diagnosis, n (%)\n\nSeverity of UC,b n (%)\n\nOverall health, n (%)\n\nPrescription medications ever taken for UC, n (%)\n\nPrescription medications currently taking for UC, n (%)\n\nIncome level,e n (%)\n\nEmployment status, n (%)\n\nEducational level, n (%)</td><td></td></tr>\r\n<tr><td>Lowi</td><td>111 (11)</td></tr>\r\n<tr><td>Middlek</td><td>261 (26)</td></tr>\r\n<tr><td>High</td><td>628 (63)</td></tr>\r\n</table>', 'table_markdown': '| Characteristics\n                                                         | Patients\n (N = 1000)\n             |\n|---------------------------------------------------------|-------------|\n| Age (years), mean (SD)                                  | 41.3 (12.6) |\n| <50, n (%)                                              | 753 (75)    |\n| >50, n (%)                                              | 247 (25)    |\n| Female, n (%)                                           | 498 (50)    |\n| Age at UC diagnosis (years), mean (SD)                  | 32.3 (12.4) |\n| Time since UC diagnosis (years), mean (SD)              | 9.0 (9.5)   |\n| Time since UC diagnosis, n (%)                          |             |\n| <1 year                                                 | 49 (5)      |\n| 1-4 years                                               | 415 (41)    |\n| 5-9 years                                               | 198 (20)    |\n| >10 years                                               | 338 (34)    |\n| Severity of UC,b n (%)                                  |             |\n| Milder UC                                               | 183 (18)    |\n| Moderate to severe UC                                   | 817 (82)    |\n| Currently in remission                                  | 676 (68)    |\n| Overall health, n (%)                                   |             |\n| Good/excellent                                          | 447 (45)    |\n| Poor/fair                                               | 553 (55)    |\n| Prescription medications ever taken for UC, n (%)       |             |\n| 5-ASAs (mesalamine, mesalazine)                         | 664 (66)    |\n| Corticosteroids                                         | 694 (69)    |\n| Biologic therapy                                        | 570 (57)    |\n| Anti-TNF biologic                                       | 538 (54)    |\n| Other biologic                                          | 120 (16)    |\n| Immunosuppressant                                       | 452 (45)    |\n| Another prescription medication                         | 204 (20)    |\n| Prescription medications currently taking for UC, n (%) |             |\n| 5-ASAs                                                  | 434 (43)    |\n| Corticosteroids                                         | 225 (23)    |\n| Biologic therapy                                        | 458 (46)    |\n| Anti-TNF biologic                                       | 395 (39)    |\n| Other biologic                                          | 84 (11)     |\n| Immunosuppressant                                       | 287 (29)    |\n| Another prescription medication                         | 110 (11)    |\n| Not currently taking prescription medication            | 50 (5)      |\n| Impact at work, n (%)                                   | 836 (84)    |\n| Took time away from work due to their UC, n (%)         | 624 (62)    |\n| Income level,e n (%)                                    |             |\n| Lowf                                                    | 238 (27)    |\n| Middle                                                  | 317 (36)    |\n| High                                                    | 284 (32)    |\n| Employment status, n (%)                                |             |\n| Not employed                                            | 250 (25)    |\n| Part-time employment                                    | 90 (9)      |\n| Full-time employment                                    | 661 (66)    |\n| Educational level, n (%)                                |             |\n| Lowi                                                    | 111 (11)    |\n| Middlek                                                 | 261 (26)    |\n| High                                                    | 628 (63)    |', 'table_width': 0.41950055956840515, 'table_x': 0.06540729105472565, 'table_y': 0.10099206119775772}, {'document_name': 'tobeingest', 'table_id': 'afe91d8e-4966-4791-bca7-93cfc1a35a69', 'table_name': 'page_6_table_1.jpg', 'table_bbox': x: 0.07232790440320969, y: 0.629601776599884, width: 0.39757418632507324, height: 0.18330639600753784, 'table_column_count': 4, 'table_title': 'B) Educational level', 'column_headers': ['Not employed employed full\n', 'time\n', 'OR\n', 'Relative\n difference\n'], 'footers': [], 'table_height': 0.18330639600753784, 'table_metadata': {}, 'table_page_number': 6, 'table_page_id': '90ab1506-4822-4e21-9a22-454a458ea0e9', 'table_confidence': 88.623046875, 'table_row_count': 9, 'table_img_path': 'tobeingest\\tables/img\\page_6_table_1.jpg', 'table_html': '<table><tr><th>Not employed employed full time</th><th></th><th>OR</th><th>Relative\n difference</th></tr>\r\n<tr><td>Stopped treatment to\n\nstart a familyb</td><td></td><td>0.11</td><td>89% less likely</td></tr>\r\n<tr><td>At least somewhat satisfied\n\nwith my medication</td><td></td><td>0.47</td><td>53% less likely</td></tr>\r\n<tr><td>Described current overall health\n\nas "good/excellent"</td><td></td><td>0.58</td><td>42% less likely</td></tr>\r\n<tr><td>Employed part time vs full time</td><td></td><td>Not employed employed full time</td><td></td></tr>\r\n<tr><td>Preventing the need for injections\n or infusions is important to\n\nmanaging my UC</td><td></td><td>0.43</td><td>57% less likely</td></tr>\r\n<tr><td>0</td><td>1</td><td>2</td><td></td></tr>\r\n<tr><td></td><td>Not employed employed full time\n\nOR (95% CI)</td><td></td><td></td></tr>\r\n<tr><td></td><td></td><td>Not employed employed full time\n\nOR (95% CI)</td><td></td></tr>\r\n</table>', 'table_markdown': '| Not employed employed full time\n                                 |             | OR\n      | Relative\n difference\n                 |\n|---------------------------------|-------------|------|-----------------|\n| Stopped treatment to\n\nstart a familyb                                 |             | 0.11 | 89% less likely |\n| At least somewhat satisfied\n\nwith my medication                                 |             | 0.47 | 53% less likely |\n| Described current overall health\n\nas "good/excellent"                                 |             | 0.58 | 42% less likely |\n| Employed part time vs full time |             |      |                 |\n| Preventing the need for injections\n or infusions is important to\n\nmanaging my UC                                 |             | 0.43 | 57% less likely |\n| 0                               | 1           | 2    |                 |\n|                                 | OR (95% CI) |      |                 |\n|                                 |             |      |                 |', 'table_width': 0.39757418632507324, 'table_x': 0.07232790440320969, 'table_y': 0.629601776599884}, {'document_name': 'tobeingest', 'table_id': 'a7932735-5e82-49d0-a9bd-ab01f9d0e6a1', 'table_name': 'page_8_table_1.jpg', 'table_bbox': x: 0.07135798782110214, y: 0.5738686323165894, width: 0.41823887825012207, height: 0.2657172977924347, 'table_column_count': 5, 'table_title': None, 'column_headers': ['OR\n', 'Relative\n difference\n'], 'footers': [], 'table_height': 0.2657172977924347, 'table_metadata': {}, 'table_page_number': 8, 'table_page_id': '33e8d23e-9677-4389-86c1-653852b3e88d', 'table_confidence': 74.4140625, 'table_row_count': 11, 'table_img_path': 'tobeingest\\tables/img\\page_8_table_1.jpg', 'table_html': '<table><tr><td></td><td></td><td></td><th>OR</th><th>Relative\n difference</th></tr>\r\n<tr><td>Described current overall health as\n\n"good/excellent"</td><td></td><td></td><td>0.41</td><td>59% less likely</td></tr>\r\n<tr><td>UC has made me more resilient</td><td>-</td><td></td><td>0.51</td><td>49% less likely</td></tr>\r\n<tr><td>UC controls my life, rather than me\n\ncontrolling the disease</td><td></td><td></td><td>1.87</td><td>87% more likely</td></tr>\r\n<tr><td>Take time off from my job due to\n\nmy disease/symptoms\n\n(not disability)</td><td></td><td></td><td>1.79</td><td>79% more likely</td></tr>\r\n<tr><td>Factors considered important to managing their UC</td><td></td><td></td><td></td><td></td></tr>\r\n<tr><td>Working more often/consistently®</td><td></td><td></td><td>1.93</td><td>93% more likely</td></tr>\r\n<tr><td>Reducing fatigue</td><td></td><td></td><td>1.92</td><td>92% more likely</td></tr>\r\n<tr><td>Less impact on my sex life and\n\npersonal relationships</td><td></td><td></td><td>1.65</td><td>65% more likely</td></tr>\r\n<tr><td>Reducing the need for prescription\n medication</td><td></td><td></td><td>1.64</td><td>64% more likely</td></tr>\r\n<tr><td>0</td><td>1</td><td>2\n3\n OR (95% CI)</td><td>4</td><td></td></tr>\r\n</table>', 'table_markdown': '|                                                   |    |    |      |                 |\n|---------------------------------------------------|----|----|------|-----------------|\n|                                                   |    |    | OR   | Relative\n difference                 |\n| Described current overall health as\n\n"good/excellent"                                                   |    |    | 0.41 | 59% less likely |\n| UC has made me more resilient                     | -  |    | 0.51 | 49% less likely |\n| UC controls my life, rather than me\n\ncontrolling the disease                                                   |    |    | 1.87 | 87% more likely |\n| Take time off from my job due to\n\nmy disease/symptoms\n\n(not disability)                                                   |    |    | 1.79 | 79% more likely |\n| Factors considered important to managing their UC |    |    |      |                 |\n| Working more often/consistently®                  |    |    | 1.93 | 93% more likely |\n| Reducing fatigue                                  |    |    | 1.92 | 92% more likely |\n| Less impact on my sex life and\n\npersonal relationships                                                   |    |    | 1.65 | 65% more likely |\n| Reducing the need for prescription\n medication                                                   |    |    | 1.64 | 64% more likely |\n| 0                                                 | 1  | 2\n3\n OR (95% CI)    | 4    |                 |', 'table_width': 0.41823887825012207, 'table_x': 0.07135798782110214, 'table_y': 0.5738686323165894}, {'document_name': 'tobeingest', 'table_id': '66ce6327-4d27-4b0e-8519-9091d85b02b5', 'table_name': 'page_9_table_1.jpg', 'table_bbox': x: 0.0761202871799469, y: 0.06446002423763275, width: 0.8563995361328125, height: 0.44429469108581543, 'table_column_count': 5, 'table_title': 'Health Care Disparities, Social Determinants, and Emotional Impacts in UC Patients', 'column_headers': ['A)\n', 'Income level\n', 'B) Educational level\n', 'C) Sex\n', 'D) Psychological comorbidities\n'], 'footers': [], 'table_height': 0.44429469108581543, 'table_metadata': {}, 'table_page_number': 9, 'table_page_id': '1733d659-0fa5-40c0-abfd-61d2fd2a9e56', 'table_confidence': 99.755859375, 'table_row_count': 16, 'table_img_path': 'tobeingest\\tables/img\\page_9_table_1.jpg', 'table_html': '<table><tr><th>A) Income level</th><th></th><th>B) Educational level</th><th>C) Sex</th><th>D) Psychological comorbidities</th></tr>\r\n<tr><td>A) Income level\n\nIf my treatment makes me feel good\n\nenough, I don\'t see a need to consider\n\nother treatment options, even if they\n\nmight make me feel even better</td><td>[ ]\nLow\n[ ]\nMiddle\n[X]\nHigh</td><td>[ ]\nLow\n[X]\nMiddle\n[X]\nHigh</td><td>[ ]\nMale\n[ ]\nFemale</td><td>[X]\nDepression\n[ ]\nAnxiety\n[ ]\nNeither</td></tr>\r\n<tr><td></td><td>61\n\n55\n\n50</td><td>59\n\n52\n\n49</td><td>65\n\n48</td><td>45\n 45\n\n60</td></tr>\r\n<tr><td>UC controls my life, rather\n than me controlling the disease</td><td>58\n\n68\n\n65</td><td>64\n 66\n\n60</td><td>67\n\n62</td><td>72\n\n69\n\n63</td></tr>\r\n<tr><td>Visited an office located\n\nin IBD center or clinic in\n\nthe past 12 months</td><td>46\n\n49\n\n38</td><td>51\n\n41\n\n36</td><td>57\n\n36</td><td>27\n\n33\n\n53</td></tr>\r\n<tr><td>Ever participated in a\n\npatient support group</td><td>43\n\n40\n\n33</td><td>43\n\n33\n\n30</td><td>36\n\n42</td><td>41\n\n48\n\n37</td></tr>\r\n<tr><td>Ever interacted with\n\npatient associations</td><td>54\n 52\n\n39</td><td>54\n\n40\n\n29</td><td>46\n 48</td><td>45\n\n51\n\n47</td></tr>\r\n<tr><td>Missed one or more events\n in the past 12 months\n due to my UC</td><td>50\n\n55\n\n47</td><td>52\n 53\n\n47</td><td>60\n\n44</td><td>44\n\n52\n 53</td></tr>\r\n<tr><td>Described current\n\noverall health as\n\n"good/excellent"</td><td>56\n\n49\n\n33</td><td>53\n\n34\n\n23</td><td>44\n 45</td><td>23\n\n36\n\n49</td></tr>\r\n<tr><td>Described current\n\noverall health as\n\n"poor/fair"</td><td>44\n\n51\n\n67</td><td>47\n\n66\n\n77</td><td>56\n 55</td><td>77\n\n64\n\n51</td></tr>\r\n<tr><td>Currently consider\n\nyour UC to be in\n\nremission</td><td>70\n 71\n\n65</td><td>70\n\n63\n 63</td><td>70\n\n65</td><td>57\n\n53\n\n71</td></tr>\r\n<tr><td>Most recent UC\n\nflare lasting\n 1 month or more</td><td>34\n\n28\n\n44</td><td>30\n\n34\n\n38</td><td>23\n\n42</td><td>34\n\n42\n\n30</td></tr>\r\n<tr><td>Hesitant to tell my gastroenterologist/\n\ninternist if don\'t take my\n\nmedication exactly as prescribed</td><td>42\n\n45\n\n40</td><td>46\n\n31\n\n42</td><td>50\n\n33</td><td>40\n 38\n\n43</td></tr>\r\n<tr><td>Worry that, if ask too many questions,\n\nmy gastroenterologist/internist will\n see me as a difficult patient and it will\n\naffect the quality of care I receive</td><td>42\n\n51\n\n36</td><td>49\n\n35\n\n42</td><td>53\n\n36</td><td>44\n 42\n\n45</td></tr>\r\n<tr><td>Have been hospitalized\n\nin the past 12 months</td><td>38\n\n52\n\n29</td><td>48\n\n35\n 36</td><td>54\n\n32</td><td>33\n\n37\n\n47</td></tr>\r\n<tr><td>Currently seeing my\n\ngastroenterologist</td><td>80\n\n73\n 75</td><td>82\n\n74\n\n67</td><td>68</td><td>81\n\n87\n\n89\n76</td></tr>\r\n</table>', 'table_markdown': '| A) Income level\n   |    | B) Educational level\n   | C) Sex\n    | D) Psychological comorbidities\n   |\n|---|----|---|----|---|\n| If my treatment makes me feel good\n\nenough, I don\'t see a need to consider\n\nother treatment options, even if they\n\nmight make me feel even better   | [ ]\nLow\n[ ]\nMiddle\n[X]\nHigh    | [ ]\nLow\n[X]\nMiddle\n[X]\nHigh   | [ ]\nMale\n[ ]\nFemale    | [X]\nDepression\n[ ]\nAnxiety\n[ ]\nNeither   |\n|   | 61\n\n55\n\n50    | 59\n\n52\n\n49   | 65\n\n48    | 45\n 45\n\n60   |\n| UC controls my life, rather\n than me controlling the disease   | 58\n\n68\n\n65    | 64\n 66\n\n60   | 67\n\n62    | 72\n\n69\n\n63   |\n| Visited an office located\n\nin IBD center or clinic in\n\nthe past 12 months   | 46\n\n49\n\n38    | 51\n\n41\n\n36   | 57\n\n36    | 27\n\n33\n\n53   |\n| Ever participated in a\n\npatient support group   | 43\n\n40\n\n33    | 43\n\n33\n\n30   | 36\n\n42    | 41\n\n48\n\n37   |\n| Ever interacted with\n\npatient associations   | 54\n 52\n\n39    | 54\n\n40\n\n29   | 46\n 48    | 45\n\n51\n\n47   |\n| Missed one or more events\n in the past 12 months\n due to my UC   | 50\n\n55\n\n47    | 52\n 53\n\n47   | 60\n\n44    | 44\n\n52\n 53   |\n| Described current\n\noverall health as\n\n"good/excellent"   | 56\n\n49\n\n33    | 53\n\n34\n\n23   | 44\n 45    | 23\n\n36\n\n49   |\n| Described current\n\noverall health as\n\n"poor/fair"   | 44\n\n51\n\n67    | 47\n\n66\n\n77   | 56\n 55    | 77\n\n64\n\n51   |\n| Currently consider\n\nyour UC to be in\n\nremission   | 70\n 71\n\n65    | 70\n\n63\n 63   | 70\n\n65    | 57\n\n53\n\n71   |\n| Most recent UC\n\nflare lasting\n 1 month or more   | 34\n\n28\n\n44    | 30\n\n34\n\n38   | 23\n\n42    | 34\n\n42\n\n30   |\n| Hesitant to tell my gastroenterologist/\n\ninternist if don\'t take my\n\nmedication exactly as prescribed   | 42\n\n45\n\n40    | 46\n\n31\n\n42   | 50\n\n33    | 40\n 38\n\n43   |\n| Worry that, if ask too many questions,\n\nmy gastroenterologist/internist will\n see me as a difficult patient and it will\n\naffect the quality of care I receive   | 42\n\n51\n\n36    | 49\n\n35\n\n42   | 53\n\n36    | 44\n 42\n\n45   |\n| Have been hospitalized\n\nin the past 12 months   | 38\n\n52\n\n29    | 48\n\n35\n 36   | 54\n\n32    | 33\n\n37\n\n47   |\n| Currently seeing my\n\ngastroenterologist   | 80\n\n73\n 75    | 82\n\n74\n\n67   | 68 | 81\n\n87\n\n89\n76   |', 'table_width': 0.8563995361328125, 'table_x': 0.0761202871799469, 'table_y': 0.06446002423763275}, {'document_name': 'tobeingest', 'table_id': 'af8499a4-cee4-49ca-8cbe-995dc8ebdc2b', 'table_name': 'page_12_table_1.jpg', 'table_bbox': x: 0.06554144620895386, y: 0.0588204599916935, width: 0.8611835241317749, height: 0.3952726423740387, 'table_column_count': 2, 'table_title': None, 'column_headers': [], 'footers': [], 'table_height': 0.3952726423740387, 'table_metadata': {}, 'table_page_number': 12, 'table_page_id': '777185fc-a80e-4920-91b5-f11e9aa52b91', 'table_confidence': 88.0859375, 'table_row_count': 1, 'table_img_path': 'tobeingest\\tables/img\\page_12_table_1.jpg', 'table_html': '<table><tr><td>8.\nAnyane-Yeboa A, Quezada S, Rubin DT, Balzora S. The impact of the\n\nsocial determinants of health on disparities in inflammatory bowel\n\ndisease. Clin Gastroenterol Hepatol. 2022;20(11):2427-2434.\n\n9. Odufalu FD, Aboubakr A, Anyane-Yeboa A. Inflammatory bowel\n\ndisease in underserved populations: lessons for practice. Curr Opin\n Gastroenterol. 2022;38(4):321-327.\n 10. Rubin DT, Hart A, Panaccione R, et al. Ulcerative Colitis\n Narrative global survey findings: communication gaps and\n\nagreements between patients and physicians. Inflamm Bowel Dis.\n\n2021;27(7):1096-1106.\n 11. Peyrin-Biroulet L, Ylänne K, Sipes A, et al. S927 The impact of\n\nthe COVID-19 pandemic on patients with ulcerative colitis: results\n\nfrom a global ulcerative colitis patient survey. Am J Gastroenterol.\n\n2022;117(10S):e672-e673.\n 12. Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied Logistic Re-\n\ngression. 3rd ed. Hoboken, NJ: John Wiley & Sons, Inc.; 2013.\n\n13. Cohen AK, Syme SL. Education: a missed opportunity for public\n\nhealth intervention. Am J Public Health. 2013;103(6):997-1001.\n\n14. Bernstein CN, Walld R, Marrie RA. Social determinants of\n\noutcomes in inflammatory bowel disease. Am J Gastroenterol.\n\n2020;115(12):2036-2046.\n\n15. Naganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe\n\nM. A prospective analysis of the incidence of and risk factors for\n opportunistic infections in patients with inflammatory bowel dis-\n\nease. J Gastroenterol. 2013;48(5):595-600.\n\n16. Stallmach A, Hagel S, Gharbi A, et al. Medical and surgical therapy\n\nof inflammatory bowel disease in the elderly - prospects and\n\ncomplications. J Crohns Colitis. 2011;5(3):177-188.\n\n17. Matsumoto S, Miyatani H, Yoshida Y. Ulcerative colitis: compar-\n\nison between elderly and young adult patients and between eld-</td><td>erly patients with late-onset and long-standing disease. Dig Dis Sci.\n\n2013;58(5):1306-1312.\n\n18. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of\n\ninflammatory bowel disease in Canada: a population-based study.\n\nAm J Gastroenterol. 2006;101(7):1559-1568.\n\n19. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology\n\nand natural history of inflammatory bowel diseases. Gastroenter-\n\nology. 2011;140(6):1785-1794.\n 20. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease:\n\nincidence, prevalence, and environmental influences. Gastroenter-\n\nology. 2004;126(6):1504-1517.\n\n21. Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depres-\n\nsive mood on relapse in patients with inflammatory bowel dis-\n\nease: a prospective 18-month follow-up study. Psychosom Med.\n\n2004;66(1):79-84.\n\n22. Mikocka-Walus A, Pittet V, Rossel JB, von Känel R; Swiss IBD\n\nCohort Study Group. Symptoms of depression and anxiety are\n\nindependently associated with clinical recurrence of inflamma-\n\ntory bowel disease. Clin Gastroenterol Hepatol. 2016;14(6):829-\n\n835.e1.\n\n23. Janke K-H, Klump B, Gregor M, Meisner C, Haeuser W.\n\nDeterminants of life satisfaction in inflammatory bowel disease.\n\nInflamm Bowel Dis. 2005;11(3):272-286.\n\n24. Nahon S, Lahmek P, Saas C, et al. Socioeconomic and psychological\n\nfactors associated with nonadherence to treatment in inflammatory\n\nbowel disease patients: results of the ISSEO survey. Inflamm Bowel\n\nDis. 2011;17(6):1270-1276.\n\n25. Sewell JL, Velayos FS. Systematic review: the role of race and so-\n\ncioeconomic factors on IBD health care delivery and effectiveness.\n\nInflamm Bowel Dis. 2013;19(3):627-643.</td></tr>\r\n</table>', 'table_markdown': '|    |    |\n|----|----|\n| 8.\nAnyane-Yeboa A, Quezada S, Rubin DT, Balzora S. The impact of the\n\nsocial determinants of health on disparities in inflammatory bowel\n\ndisease. Clin Gastroenterol Hepatol. 2022;20(11):2427-2434.\n\n9. Odufalu FD, Aboubakr A, Anyane-Yeboa A. Inflammatory bowel\n\ndisease in underserved populations: lessons for practice. Curr Opin\n Gastroenterol. 2022;38(4):321-327.\n 10. Rubin DT, Hart A, Panaccione R, et al. Ulcerative Colitis\n Narrative global survey findings: communication gaps and\n\nagreements between patients and physicians. Inflamm Bowel Dis.\n\n2021;27(7):1096-1106.\n 11. Peyrin-Biroulet L, Ylänne K, Sipes A, et al. S927 The impact of\n\nthe COVID-19 pandemic on patients with ulcerative colitis: results\n\nfrom a global ulcerative colitis patient survey. Am J Gastroenterol.\n\n2022;117(10S):e672-e673.\n 12. Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied Logistic Re-\n\ngression. 3rd ed. Hoboken, NJ: John Wiley & Sons, Inc.; 2013.\n\n13. Cohen AK, Syme SL. Education: a missed opportunity for public\n\nhealth intervention. Am J Public Health. 2013;103(6):997-1001.\n\n14. Bernstein CN, Walld R, Marrie RA. Social determinants of\n\noutcomes in inflammatory bowel disease. Am J Gastroenterol.\n\n2020;115(12):2036-2046.\n\n15. Naganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe\n\nM. A prospective analysis of the incidence of and risk factors for\n opportunistic infections in patients with inflammatory bowel dis-\n\nease. J Gastroenterol. 2013;48(5):595-600.\n\n16. Stallmach A, Hagel S, Gharbi A, et al. Medical and surgical therapy\n\nof inflammatory bowel disease in the elderly - prospects and\n\ncomplications. J Crohns Colitis. 2011;5(3):177-188.\n\n17. Matsumoto S, Miyatani H, Yoshida Y. Ulcerative colitis: compar-\n\nison between elderly and young adult patients and between eld-    | erly patients with late-onset and long-standing disease. Dig Dis Sci.\n\n2013;58(5):1306-1312.\n\n18. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of\n\ninflammatory bowel disease in Canada: a population-based study.\n\nAm J Gastroenterol. 2006;101(7):1559-1568.\n\n19. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology\n\nand natural history of inflammatory bowel diseases. Gastroenter-\n\nology. 2011;140(6):1785-1794.\n 20. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease:\n\nincidence, prevalence, and environmental influences. Gastroenter-\n\nology. 2004;126(6):1504-1517.\n\n21. Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depres-\n\nsive mood on relapse in patients with inflammatory bowel dis-\n\nease: a prospective 18-month follow-up study. Psychosom Med.\n\n2004;66(1):79-84.\n\n22. Mikocka-Walus A, Pittet V, Rossel JB, von Känel R; Swiss IBD\n\nCohort Study Group. Symptoms of depression and anxiety are\n\nindependently associated with clinical recurrence of inflamma-\n\ntory bowel disease. Clin Gastroenterol Hepatol. 2016;14(6):829-\n\n835.e1.\n\n23. Janke K-H, Klump B, Gregor M, Meisner C, Haeuser W.\n\nDeterminants of life satisfaction in inflammatory bowel disease.\n\nInflamm Bowel Dis. 2005;11(3):272-286.\n\n24. Nahon S, Lahmek P, Saas C, et al. Socioeconomic and psychological\n\nfactors associated with nonadherence to treatment in inflammatory\n\nbowel disease patients: results of the ISSEO survey. Inflamm Bowel\n\nDis. 2011;17(6):1270-1276.\n\n25. Sewell JL, Velayos FS. Systematic review: the role of race and so-\n\ncioeconomic factors on IBD health care delivery and effectiveness.\n\nInflamm Bowel Dis. 2013;19(3):627-643.    |', 'table_width': 0.8611835241317749, 'table_x': 0.06554144620895386, 'table_y': 0.0588204599916935}]
